Trial · NCT01854632
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Participants With Symptomatic, Laboratory-confirmed Influenza Virus Infection (Regardless of Vaccine Match) | Through 7 to 8 months post vaccination | |
| Secondary | Safety Profile of LAIV: Immediate Reactions Occurring Within 30 Minutes of Administration of Study Vaccine. | Through 30 minutes post vaccination | |
| Secondary | Safety Profile of LAIV: Solicited and Unsolicited Local and Systemic Reactions | Through 7 days post vaccination | |
| Secondary | Safety Profile of LAIV: Serious Adverse Events | Through 1 month post vaccination | |
| Secondary | Safety Profile of LAIV: Other Non-serious Adverse Events | Through 1 month post vaccination | |
| Secondary | Safety Profile of LAIV: Protocol Defined Wheezing Illness | Through 7 to 8 months post vaccination | |
| Secondary | Percentage of Participants With Symptomatic, Laboratory-confirmed Influenza Virus Infection (Vaccine-matched Strains) | Through 7 to 8 months post vaccination | |
| Secondary | Percentage of Participants With Symptomatic, Laboratory-confirmed Influenza Virus Infection by Influenza Type/Subtype (Influenza A/H1N1, Influenza A/H3N2, and Influenza B) | Through 7 to 8 months post vaccination | |
| Secondary | Clinical Characteristics of Influenza in the Study Population | Through 7 to 8 months post vaccination | |
| Secondary | Etiologies of Influenza-like Illness in the Study Population | Through 7 to 8 months post vaccination | Bacterial and viral etiologies of acute respiratory and febrile illness will be parameterized as the percentage of those with each particular laboratory-confirmed infection categorized by vaccine allocation. |
| Secondary | Evaluation of Vaccine-take as Shedding of Vaccine Virus Post-vaccination, Including Viral Load and Duration of Virus Detection | Through 4 days post vaccination | Vaccine take will be parameterized as the percentage of participants with detectable vaccine-virus in nasal or throat swab on each day pre- (day 0) and post vaccination (i.e., 2 and 4 days post vaccination), and the quantity of detected virus. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01854632/registered